Key Highlights
- Shares of Relmada Therapeutics climbed approximately 31% during premarket hours Monday following dual catalysts
- Phase 2 interim data for NDV-01 demonstrated an impressive 76% complete response rate at 12 months for bladder cancer patients
- A heavily oversubscribed private placement raised $160 million at $4.75 per share
- The financing arrangement encompasses 29.47 million shares plus pre-funded warrants covering 4.21 million additional shares, with March 11 closing date
- Analyst sentiment remains bullish with a Strong Buy rating and $10.25 average target price
The company unveiled interim results from its Phase 2 clinical study evaluating NDV-01 for treating high-risk non-muscle invasive bladder cancer (NMIBC). Data revealed a 12-month complete response rate reaching 76%, accompanied by a well-tolerated safety profile. Notably, this response threshold was achieved among BCG-unresponsive patients as well.
Dr. Raj S. Pruthi, Relmada’s Chief Medical Officer of Oncology, described the findings as providing “meaningful clinical validation” for the development program.
Relmada Therapeutics, Inc., RLMD
Management announced intentions to progress NDV-01 into a pivotal Phase 3 registrational study dubbed the RESCUE program, featuring dual tracks: one targeting BCG-unresponsive patients and another focused on adjuvant intermediate-risk cases. Launch of the Phase 3 trial is anticipated around mid-2026.
Major Capital Infusion Through Private Placement
Concurrently with the clinical update, Relmada disclosed completion of an oversubscribed $160 million private investment in public equity (PIPE).
The financing structure includes 29,474,569 ordinary shares sold at $4.75 apiece, alongside pre-funded warrants covering 4,210,527 additional shares at $4.749 with minimal exercise price of $0.001.
Jefferies, Leerink Partners, Piper Sandler, and Mizuho serve as placement agents for the transaction. Closing is scheduled for March 11, 2026, pending customary closing conditions.
The capital will fund operational needs and support ongoing research and development initiatives.
Investors received resale registration rights as part of the agreement. Relmada agreed to maintain compliant SEC filings, with potential liquidated damages of 1.0% monthly for missed deadlines, subject to specified limits.
Market Reaction and Performance
RLMD shares surged 31.01% in premarket action Monday morning. The stock had recorded modest gains during Friday’s session.
For the current year, shares remain down 7.87%. However, the trailing 12-month performance shows remarkable growth of 1,536%.
Trading activity exploded following the announcements. More than 7.9 million shares traded hands Monday, dramatically exceeding the three-month average daily volume of approximately 570,000.
This volume spike — exceeding 13 times normal levels — demonstrates significant market interest sparked by both announcements.
Wall Street analysts maintain a Strong Buy consensus rating on RLMD, supported by four Buy recommendations issued within the last three months.
The consensus price target stands at $10.25, suggesting potential upside of roughly 130% from present trading levels.
